RT Journal Article
SR Electronic
T1 A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252709
DO 10.1101/2021.03.05.21252709
A1 Banada, Padmapriya
A1 Green, Raquel
A1 Banik, Sukalyani
A1 Chopoorian, Abby
A1 Streck, Deanna
A1 Jones, Robert
A1 Chakravorty, Soumitesh
A1 Alland, David
YR 2021
UL http://medrxiv.org/content/early/2021/04/08/2021.03.05.21252709.abstract
AB Background The increased transmission of SARS-CoV-2 variants of concern (VOC) which originated in the United Kingdom (B.1.1.7), South Africa (B1.351), Brazil (P.1) and in United States (B.1.427/429) requires a vigorous public health response, including real time strain surveillance on a global scale. Although genome sequencing is the gold standard for identifying these VOCs, it is time consuming and expensive. Here, we describe a simple, rapid and high-throughput reverse-transcriptase PCR (RT-PCR) melting temperature (Tm) screening assay that identifies these three major VOCs.Methods RT-PCR primers and four sloppy molecular beacon (SMB) probes were designed to amplify and detect the SARS-CoV-2 N501Y (A23063T) and E484K (G23012A) mutations and their corresponding wild type sequences. After RT-PCR, the VOCs were identified by a characteristic Tm of each SMB. Assay optimization and testing was performed with RNA from SARS-CoV-2 USA WA1/2020 (WT), a B.1.17 and a B.1.351 variant strains. The assay was then validated using clinical samples.Results The limit of detection (LOD) for both the WT and variants was 4 and 10 genomic copies/reaction for the 501 and 484 codon assays, respectively. The assay was 100% sensitive and 100% specific for identifying the N501Y and E484K mutations in cultured virus and in clinical samples as confirmed by Sanger sequencing.Conclusion We have developed an RT-PCR melt screening test for the three major VOCs which can be used to rapidly screen large numbers of patient samples providing an early warning for the emergence of these variants and a simple way to track their spread.Competing Interest StatementD.A. receives research support and royalty payments from Cepheid, which sells the Xpert Xpress SARS-CoV-2 and Xpert Xpress SARS-CoV-2/Flu/RSV tests., S.C, is an employee of Cepheid and R.J. is a paid consultant for Cepheid.Clinical TrialBanked clinical specimens that were collected either for routine diagnostics or other research studies unrelated to the current manuscript were tested in this study.Funding StatementThis study was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01 AI131617.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of de-identified clinical samples from confirmed COVID-19 positive and negative patients for PCR testing and sequencing was approved by the Rutgers Institutional Review Board under protocol numbers 20170001218 and 2020001541.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe assay published here along with the primers and probes are made available freely for the readers